A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer

Trial Profile

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs MM 302 (Primary) ; Cyclophosphamide; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 15 Mar 2017 Results of enhanced permability and retention using 64Cu-labeled nanoparticle (64Cu-MM-302; n=19) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 15 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top